Novo Nordisk Introduces Discounted Wegovy Subscription Plans via Telehealth Platforms

Novo Nordisk Introduces Discounted Wegovy Subscription Plans via Telehealth Platforms
1 min readBusinessHealth

In Brief

The new subscription model may expand access to obesity treatments and intensify competition with Eli Lilly in the weight-loss drug market.

Key Facts

  • Novo Nordisk has launched multi-month subscription plans for its Wegovy obesity drugs.
  • Longer subscriptions offer lower monthly pricing, with potential savings of up to $1,200 a year for the injection and $600 a year for the pill.
  • Discounts in the new subscription plan can reach nearly 30%.
  • The program is available from Tuesday through telehealth platforms such as Ro, WeightWatchers, and LifeMD.
  • The initiative is seen as an effort to catch up with Eli Lilly in the obesity drug sector.

What Happened

Novo Nordisk announced new multi-month subscription plans for its Wegovy obesity drugs, featuring significant discounts and availability through several telehealth providers.

Why It Matters

This move could make obesity medications more affordable for patients and signals increased competition in the fast-growing weight-loss drug market, potentially influencing pricing and access.

What's Next

Observers will watch for patient uptake of the new plans and any competitive responses from other pharmaceutical companies, particularly Eli Lilly.

Sources